Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Real-world Study of Inetetamab for First-line Treatment of HER2-positive Inoperable Locally Advanced or Relapsed Metastatic Breast Cancer

NCT05980208 is registered in ClinicalTrials.gov with Hunan Cancer Hospital as lead sponsor.

NCT NCT05980208
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05980208 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Real-world Study of Inetetamab for First-line Treatment of HER2-positive Inoperable Locally Advanced or Relapsed Metastatic Breast Cancer
Lead sponsor
Hunan Cancer Hospital
Phase
Observational
Overall status
Not yet recruiting
Start date
September 1, 2023
Completion date
December 31, 2026
Enrollment
150 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, real-world study